Company news
Inflarx N.v. (NASDAQ:IFRX) news
Inflarx N.v. news releases on 6ix. Latest, Oct 2, 2026: InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Press releases & updates
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
October 1, 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
October 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development
October 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
September 30, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
October 1, 2026
InflaRx to Host Virtual Capital Markets Day
September 21, 2026
InflaRx Announces Participation in September Investor Conferences
August 20, 2026
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
August 6, 2026
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
July 30, 2026
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
June 30, 2026
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
May 8, 2026
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
May 6, 2026
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 4, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 1, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 8, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
March 31, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
March 30, 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
March 18, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
March 17, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
March 12, 2026
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
February 26, 2026
InflaRx Announces Participation in February Investor Conferences
January 29, 2026
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
January 8, 2026
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
December 30, 2025
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
December 11, 2025
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
November 10, 2025
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
November 7, 2025
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
October 21, 2025
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 12, 2025
InflaRx Announces Participation in September Investor Conferences
August 21, 2025
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
July 31, 2025
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
July 11, 2025
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
May 28, 2025
InflaRx to Participate in Upcoming Investor Conferences
May 22, 2025
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
InflaRx to Report First Quarter 2025 Results on May 7, 2025
April 30, 2025
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
March 20, 2025
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
March 7, 2025
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
February 28, 2025
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
February 25, 2025
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
February 18, 2025
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
February 12, 2025
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
February 12, 2025
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
January 14, 2025
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
December 19, 2024
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
November 14, 2024
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
October 30, 2024
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
September 24, 2024